Category: Medical Research & Technology

Categories : Cardiovascular Disease Medical Research & TechnologyTags :

New Early Warning System for Sudden Cardiac Death

On By ModernMedia
Photo from Olivier Collett on Unsplash
Photo from Olivier Collett on Unsplash

Researchers at Tomsk Polytechnic University have developed a nanosensor-based system that can detect early abnormalities in the function of cardiac muscle cells, which otherwise can be recorded only with invasive procedures.

The nanosensor-based hardware and software complex can measure cardiac micropotential energies without filtering and averaging-out cardiac cycles in real time. The device allows registering early abnormalities in the function of cardiac muscle cells, which otherwise can be recorded only during open-heart surgery or by inserting an electrode in a cardiac cavity through a vein. Such changes can lead to sudden cardiac death (SCD). Nowadays, there are no alternatives to the Tomsk device for a number of key characteristics in Russia and the world. ).

The main method of detection of electrical pulses in the heart is electrocardiography (ECG). Nevertheless, ECG modern devices detect already critical changes in the function of the myocardium.

“Therefore, there is much concern about the creation of devices for early detection of these disorders, when it is still possible to restore cell function using medication and without surgical intervention. To implement this, it is required to record cardiac micropotential energies, electrical pulses emitted by separate cells. Here, there is a question of how to implement it noninvasive. Our research team have worked on this task for a long time, as a consequence, we jointly with the participation of our colleagues, doctors, have developed a hardware and software complex.

“The core principles of its operation are similar to ECG, however, we changed sensors: we made nanosensors instead of conventional sensors and managed to measure signals of nanovoltage and microvoltage layers without filtering and averaging-out in broadband. The use of nanosensors led to the necessity to apply original circuit solutions, write individual software.

“Ultimately, we gained a tremendous difference in sensitivity,” Diana Avdeeva, Head of the TPU Laboratory for Medical Engineering, a research supervisor of the project, said.

The system consists of a set of sensors, a tiny key device for recording incoming signals from sensors and data processing software. The sensors are fixed on a patient’s chest using a conducting gel, and the monitoring procedure takes about 20 minutes.

Conventional ECG machines operate on frequencies from 0,05 Hz to 150 Hz, while the device of the Tomsk scientists operates on much higher frequencies of up to 10 000 Hz.

“Silver chloride electrodes are usually used for recording ECG of high quality. Our sensors are also silver chloride electrodes, however, we used silver nanoparticles. There are up to 16 thin plates from porous ceramics in every our sensor, silver nanoparticles are placed in these pores. There are millions of particles in one sensor, where every particle is a silver chloride electrode capable to enhance an electric field of the heart. Silver and gold nanoparticles are capable to enhance an electromagnetic field: visible light by 10,000 folds and infrared radiation by 20 folds. We also refused to use filters for rejection network interference and noises, which are usually used in conventional ECG and significantly distort micropotentials,” Diana Avdeeva said.

The published study includes the monitoring data of one volunteer’s heart function, who took part in the research for four years and was monitored every 7-10 days.

“At the beginning of our research, we recorded clear violations of activity of cardiac muscle cells. His attending physician recommended surgery, he gained an inserted stent at the Cardiology Research Institute. Then, he continued to take part in the research and the device recorded the further gradual restoration of cardiac function,” the scientist noted.

“A task to create a sensitive, tiny and affordable complex was set up, in order in a long run, outpatient clinics and patients at home could use it. Moreover, the developed methods and devices can be used not only in cardiology.

“The fields of any electrophysiological research, such as electroencephalography, electromyography and so on are promising. Of course, before applying it to cardiology, we have to pass some essential stages. These are the collection of the required array of statistics, certification of the complex for medical use. All these stages require sponsorship, we are engaged in searching for partners and supporting programs,” said research team member Mikhail Yuzhakov, Engineer at the TPU Laboratory for Medical Engineering.

Source: Tomsk Polytechnic University

Categories : Medical Research & Technology Pain ManagementTags :

Researchers Test VR in Treatment of Chronic Pain

On By ModernMedia
Photo by Bradley Hook from Pexels

A team of researchers at the University of East Anglia are starting a new project to see if virtual reality, combined with an innovative brain interface could help with the treatment of chronic pain.

Almost one in five South African adults are living with chronic pain, and the team will study whether new technology delivered via a VR headset could help ease their symptoms.

One very science-fiction-like aspect of the study the use of a ‘Brain-Computer Interface’ where participants will be taught to control elements of a VR game using only their thoughts. Previous studies have shown that VR therapy was effective in reducing chronic and acute pain in children and adults.  

Dr Jordan Tsigarides from UEA’s Norwich Medical School and a Rheumatology doctor at the Norfolk and Norwich University Hospital, said: “Virtual Reality is an emerging technology where the user gains a completely immersive, interactive and often transformative experience with the use of a head-mounted display.

“VR seems to flood the brain with a multitude of audiovisual signals, engaging the senses and diverting the brain’s attention from processing pain signals.”

“At present, there is evidence that VR can significantly decrease people’s acute pain. What we are looking to find out is whether this kind of technology can be used to help people suffering chronic pain as well.”

The team is working with industry partner, Orbital Innovations, and has developed an innovative VR program for patients with chronic pain conditions, such as fibromyalgia syndrome and chronic pain following a total knee replacement. It will be tested on patients recruited from the NNUH and Addenbrookes in partnership with rheumatology, orthopaedics and pain management departments.

Dr Tsigarides said: “The virtual worlds that we have created aim to transport patients to naturalistic, immersive environments whether its travelling down a cool snowy river or planting crops in a luscious warm forest. Through VR, we aim to engage patients through challenging and interactive games, with the objective of understanding more about how this technology can reboot the brain’s pain networks.

“We are working with neuroscientists at the UEA to look at the brain waves of people with chronic pain. This has the potential to allow us to see how this technology is working, as well as learn more about the brain function of people with these conditions.

“Moving things with your mind sounds like something straight from a sci-fi movie but with today’s technology, ‘Brain-Computer Interfaces’ are being used more and more in health research. We believe that this exciting new innovation when coupled with an immersive VR experience will ‘power up’ the pain relief seen with VR alone.

“Given that just under 28 million adults in the UK suffer from chronic pain, and that we are in the midst of an opioid epidemic, this treatment could be an important future intervention.”

Peter Brady, CEO of Orbital Innovations, said: “Orbital Innovations has been working towards the development of a virtual reality technology, which will offer a way of mitigating the effects of chronic pain. This innovative project collaboration with UEA, will be breaking new ground in fully exploring the exciting opportunities this technology will offer patients in the future.”

Source: University of East Anglia

Categories : Medical Research & Technology NeurologyTags :

Brain-computer Interface Lets Paralysed People Write Letters

On By ModernMedia
Image by Gerd Altmann from Pixabay

Researchers have developed a new brain-computer interface (BCI) that can let paralysed people write by mentally writing letters by hand.

Working with a participant with paralysis who has sensors implanted in his brain, the team used an algorithm to identify letters in real time as he attempted to write them, putting the results on a screen.

This technology could be further developed to allow people with paralysis type rapidly without using their hands, said study coauthor Krishna Shenoy, a Howard Hughes Medical Institute Investigator at Stanford University who jointly supervised the work with Jaimie Henderson, a Stanford neurosurgeon.

By attempting handwriting, the study participant was able to ‘type’ 90 characters per minute — more than double the previous record for typing with such a brain-computer interface.

Thought-powered communication

Even if injury or disease the ability to move, the brain’s neural activity for being able to do so remains. By making use of this activity, researchers can help people with paralysis or amputations regain lost abilities.

In recent years, Shenoy’s team has decoded the neural activity associated with speech in the hopes of reproducing it. Patients with implanted sensors mentally pointed at and clicked on letters on a screen to type at about 40 characters per minute, the previous speed record for typing with a BCI.
Wanting to try something new and different, Frank Willett, a neuroscientist in Shenoy’s group, wondered if it might be possible to harness the brain signals evoked by writing by hand “We want to find new ways of letting people communicate faster,” he said. 

The team worked with a participant enrolled in a clinical trial involving BCIs. Henderson implanted two tiny sensors into the part of the brain that controls the hand and arm, making it possible for the person to, for example, move a robotic arm or a cursor on a screen by attempting to move their own paralysed arm.
The participant, who was 65 years old at the time of the research, had a spinal cord injury that left him paralysed from the neck down. A machine learning algorithm recognised the patterns his brain produced when he attempted to write each letter.

With this system, the man could copy sentences and answer questions at a rate similar to that of someone his age typing on a smartphone. The reason why this so-called “Brain-to-Text” BCI is so fast is because each letter elicits a highly distinctive activity pattern, making it relatively easy for the algorithm to distinguish one from another, Willett explained.

A new system

Shenoy’s team envisions using attempted handwriting for text entry as part of a more comprehensive system that also includes point-and-click navigation, much like that used on current smartphones, and even attempted speech decoding. “Having those two or three modes and switching between them is something we naturally do,” he said.
The team intends to next work with a participant who cannot speak, such as a person with amyotrophic lateral sclerosis, a degenerative neurological disorder leading to loss of movement and speech.

The new system could potentially help those suffering from paralysis caused by a number of conditions, Henderson added. Those include brain stem stroke, which afflicted Jean-Dominique Bauby, the author of the book The Diving Bell and the Butterfly. “He was able to write this moving and beautiful book by selecting characters painstakingly, one at a time, using eye movement,” Henderson said. “Imagine what he could have done with Frank’s handwriting interface!”

Source: Howard Hughes Medical Institute

Categories : Medical Research & Technology Mental HealthTags :

Distraction a Big Problem in Teletherapy Sessions

On By ModernMedia
Photo by Tracy le Blanc from Pexels

A small survey has found that although therapists appear to prefer virtual sessions over in-person meetings, a significant proportion admit to being distracted while delivering care.

A third of respondents admitted to providing lower-quality care to clients during online sessions. Overall, 39% admitted to checking emails and social media while providing virtual care.

These were the results of a survey of 600 therapists conducted and published by OnlineTherapy.com, a virtual directory for teletherapists and counselors. It’s also an affiliate of the controversial app BetterHelp, stating on their website that the company “may receive compensation from BetterHelp if you purchase products or services through the links provided.”

Online care is generally well received by therapists: nearly half said they prefer virtual sessions over in-person meetings. They appreciated many advantages of virtual therapy, such as working from home which allows therapists to keep a flexible schedule and increases their availability. Video sessions also provide therapists with a uniquely intimate look into their clients’ daily lives, making assessing their mental health easier.

However, teletherapy has introduced its own challenges. Besides the struggle to remain for therapists to stay focused themselves, 56% of those surveyed said their clients are more easily distracted during virtual sessions, and 48% reported technological issues as a major impediment to their practice.

Peter Yellowlees, MD, of UC Davis Health in Sacramento, California, noted with concern and confusion that 16% of therapists reported substance use before or during their sessions.

“There are all sorts of people in this world who call themselves therapists, most of whom have very reasonable training, but quite a number don’t,” Dr Yellowlees told MedPage Today, expressing serious doubts about whether these rates of social media distraction and substance use during virtual sessions would ring true for mental health clinicians with PhDs and MDs.

According to a spokesperson from OnlineTherapy.com, the survey only asked if respondents were currently practicing mental health professionals and did not ask for their credentials or certifications.

The results of the survey did, however, echo Dr Yellowlees’s own concerns of mental health problems on the rise of among therapists in general. The vast majority (90%) said that during the last year they suffered mental health issues, including anxiety disorders (50%) and depressive disorder (48%). This would likely impact the level of care that a therapist able to provide to their clients.

A further concern is that 17% of respondents reported seriously considered suicide since the start of the pandemic.

But  Dr Yellowlees also sees teletherapy as a way for therapists to start getting the help that they need, rather than simply treating themselves in fear of stigma or possible repercussions for their licences.

“It’s undoubtedly helped significantly,” Dr Yellowlees said. “We know that certain teletherapies are actually good for the mental health of providers, as well as the patients.”

Source: MedPage Today

Categories : Cardiovascular Disease Medical Research & TechnologyTags :

Manganese Sharpens MRI Scans of Heart Attacks

On By ModernMedia
Clinician prepares an MRI scanner. Image by Michal Jarmoluk from Pixabay

Manganese, a common trace mineral, could improve MRI scans of hearts after a heart attack and guide therapy, according to a new study.

By far the most widely used contrast agent for MRI is gadolinium, which improves the visibility of different organs and tissue types in MRI scans. However, it is taken up equally by cells regardless of their activity, and spreads out in damaged tissue. Furthermore, there are also extremely rare instances of serious kidney damage from its use. 

Manganese, besides being less toxic, has a useful property in that it competes with calcium uptake. Calcium handling is highly sensitive to altered heart muscle viability and changes rapidly after damage. Manganese ions enter heart muscle cells through calcium channels, and thus give a useful surrogate for heart tissue viability.

The contrast agent was tested first in vitro with heart muscle cells, and then in mice which had a myocardial infarction (heart attack) induced. The manganese contrast agent was administered with a calcium supplement or administered slowly to negate the effects of manganese interfering with the heart’s calcium channel. Findings were evaluated by examining the infarct size and blood supply at three key intervals: one hour, one day and 14 days after a myocardial infarction was induced. Overall, the manganese contrast agent was superior to gadolinium.

These findings could have major implications for heart attack treatment, if confirmed. They could also be greatly useful in preclinical evaluation of treatments for patients with cardiac ischaemia – where blood supply to the heart muscle is reduced, possibly leading to cardiac arrest.

Furthermore, if manganese-enhanced MRI is performed within the first few hours of a heart attack it could be used to determine the optimal treatment regime for individual patients – helping to regulate changes in the cardiac muscle and thereby further improving survival chances. 

“Magnetic resonance imaging (MRI) is increasingly used to diagnose and give information on heart conditions,” said lead researcher Dr Patrizia Camelliti, Senior Lecturer in Cardiovascular Science, University of Surrey. “This research using mice allows us to measure the health status of the heart muscle rapidly after a heart attack and could provide important information for optimizing treatments in patients.”

Source: News-Medical.Net

Journal reference: Jasmin, N.H., et al. (2021) Myocardial Viability Imaging using Manganese‐Enhanced MRI in the First Hours after Myocardial Infarction. Advanced Science. doi.org/10.1002/advs.202003987.

Categories : Immunology Medical Research & Technology New Compounds and TreatmentsTags :

New Treatment may Regenerate Liver Scarring

On By ModernMedia

Japanese researchers have come up with a new approach that could revolutionise the treatment and prevention of liver disease damage and possibly regenerate liver scarring.

This novel strategy involves small extracellular vesicles (sEVs), which are lipid-enclosed particles that are naturally released from a cell. The ones used in this study derived from interferon-γ (IFN-γ) pre-conditioned MSCs (γ-sEVs).

Cirrhosis (scarring of the liver) and other chronic liver diseases result in up to 2 million deaths reported annually around the world, these in turn account for approximately 3.5% of annual deaths globally. As the only treatment for clinically advanced cirrhosis liver transplantation, targeted therapies for modulating fibrosis and aiding tissue regeneration.  The ability to control fibrosis–the growth of fibrous tissue in response to damage– is often lost in livers under advanced cirrhosis.  The research builds upon this.

One of the most popular approaches is cell therapy, where mesenchymal stromal cells (MSCs) and macrophages have shown the potential to reduce liver fibrosis. MSCs are able to transform into a number of different cells. They are cost-effective, being available not only from bone marrow, but also from medical waste such as umbilical cord tissue, adipose (fatty) tissue, and dental pulp.

Apart from the ease of availability, MSCs can also be lab-grown. MSCs don’t replace tissue but instead have been shown to be medical signaling cells that indirectly produce cytokines, chemokines, growth factors, and exosomes that are crucial for repairing and regenerating damaged tissue.

Previous research showed that MSCs have anti-inflammatory, anti-fibrotic, and anti-oxidative effects through these humoural factors. MSCs also have lower potential for provoking an immune response and therefore rejection, enabling their use in both within the same individual and another.

In a series of experimental mice studies, researchers pre-conditioned fat extracellular vesicles with interferon gamma (IFN-γ), an important immune system signaller. They showed that this increases the number of anti-inflammatory macrophages, which are the key players in tissue repair, reducing fibrosis and promoting tissue regeneration.

They reported that both MSCs derived from fatty tissue (AD-MSC-sEVs) and AD-MSC-γ-sEVs can boost macrophage motility and phagocytic activity. In addition, they also show that AD-MSC-γ- sEVs can effectively control inflammation and fibrosis in mice with cirrhosis.

They found thatAD-MSC-derived sEVs can affect the shape and function of macrophages, effectively recruiting them into damaged areas to initiate tissue repair.

In an interview, researcher Dr Atsunori Tsuchiya at Niigata University, explained that, “Both mesenchymal stromal cells and macrophages are reported to have therapeutic effects for liver cirrhosis, however relationship of both cells and mechanisms of action was not clear. We challenged this problem.”

He continued, “We found the important fact that extracellular vesicles from interferon-γ can induce the tissue repair macrophages, which can regress fibrosis and promote liver regeneration effectively.” 

Dr Suguru Takeuchi, another of the researchers at Niigata University, concurred: “In our previous study, we reported that intravenous administration of mesenchymal stromal cells migrated to the lung, can work as ‘conducting cells’ and affect to macrophages ‘working cells’ in the liver.

“In this study we first elucidated that extracellular vesicles from mesenchymal stromal cells are key molecules to affect the macrophages.”

This study, which complements macrophage therapy, holds potential as a strategy for treating liver diseases using small extracellular vesicles pre-conditioned with IFN-γ. However, further development is needed, as well as uncovering the mechanisms by which they increase Treg cell count.

“Our results showed that modified extracellular vesicles can become a new therapeutic strategy for liver cirrhosis,” said Professor Shuji Terai, Niigata University.

Source: News-Medical.Net

Journal information: Takeuchi, S., et al. (2021) Small extracellular vesicles derived from interferon-γ pre-conditioned mesenchymal stromal cells effectively treat liver fibrosis. npj Regenerative Medicine. oi.org/10.1038/s41536-021-00132-4.

Categories : Medical Research & TechnologyTags :

A 3D Printed Hydrogel With Self-healing Capacity

On By ModernMedia

Much research has focused on hydrogels, polymer-based materials containing large amounts of water, but hydrogels with both self-healing and complex construction have proved elusive until now. 

Hydrogels need to fulfil two key criteria if they are to be effective replacements for organic tissue: the ability to form extremely complex shapes, and to self-heal after sustaining damage. Previously, hydrogels created in the laboratory had either the capability of being 3D printed into complex shapes, or had the ability to self-heal. This research realises the first time these two capabilities had been combined into one material.

The development of these materials may now be easier, and cheaper, thanks to the use of 3D printing: the researchers in the MP4MNT (Materials and Processing for Micro and Nanotechnologies) team of the Department of Applied Science and Technology of the Politecnico di Torino, coordinated by Professor Fabrizio Pirri. The researchers detailed their work in the prestigious journal Nature Communications.

In addition, the hydrogel was created using both commercially available materials and printer, thus making the approach proposed extremely flexible and potentially applicable anywhere, throwing open the door for development in the fields of both biomedicine and soft robotics.

The research was carried out in the context of the HYDROPRINT3D doctoral project, funded by the Compagnia di San Paolo, in the frame of “Joint Research Projects with Top Universities” initiative, by the PhD student Matteo Caprioli, under the supervision of the DISAT researcher Ignazio Roppolo, in collaboration with Professor Magdassi’s research group of the Hebrew University of Jerusalem (Israel).
The researchers used the digital pulsed light to create a semi-interpenetrated structure of polymer strands that, when severed, could rejoin in 12 hours at room temperature with no outside intervention. The restored section retains 72% of its initial strength.

“[For] many years, in the MP4MNT group, a research unit coordinated by Dr Annalisa Chiappone and I, specifically devoted to development of new materials that can be processed using 3D printing activated by light,” said Ignazio Roppolo, Researcher, DISAT. “3D printing is able to offer a synergistic effect between the design of the object and the intrinsic properties of materials, making [it] possible to obtain manufactured items with unique features.

“From our perspective, we need to take advantage of this synergy to best develop the capabilities of 3D printing, so that this can truly become an element of our everyday life. And this research falls right in line with this philosophy.”

This research represents a first step towards the development of highly complex devices, which can exploit both the complex geometries and the intrinsic self-healing properties in various application fields. Once biocompatibility studies have been refined, it will be possible to use these structures both for cellular mechanism research and for regenerative medicine applications.

Source: News-Medical.Net

Journal reference: Caprioli, M., et al. (2021) 3D-printed self-healing hydrogels via Digital Light Processing. Nature Communications. doi.org/10.1038/s41467-021-22802-z.

Categories : COVID Medical Research & TechnologyTags :

‘Nanotraps’ Capture COVID Virus and Prevent Infection

On By ModernMedia

Researchers have developed an entirely new treatment for COVID: ‘Nanotraps’ that capture the viruses inside the body, allowing the immune systems to destroy them

The “Nanotraps” mimick the human cells the virus normally attaches to, and bind it to their surface, keeping the virus from reaching other cells and target it for destruction by the immune system. It is possible that Nanotraps could be used on SARS-CoV-2 variants, and could be administered as a nasal spray.

“Since the pandemic began, our research team has been developing this new way to treat COVID-19,” said Assistant Professor Jun Huang, whose lab led the research. “We have done rigorous testing to prove that these Nanotraps work, and we are excited about their potential.”

Postdoc Min Chen and graduate student Jill Rosenberg targeted the spike mechanism that SARS-CoV-2 uses to lock onto ACE2 proteins on human cells.

To create a trap that would bind to the virus in the same way, they designed nanoparticles with a high density of ACE2 proteins on their surface. Other nanoparticles were designed with neutralising antibodies on their surfaces.

ACE2 proteins and neutralising antibodies have both been used in COVID treatments, but by mounting them onto nanoparticles, a much more effective and robust means for trapping the virus was created.

The nanoparticles are smaller than cells, 500 nanometres in diameter, allowing them to reach deep inside tissue and trap the virus.

No evidence of toxicity was seen in tests with mice, and they then tested the Nanotraps against a non-replicating virus called a pseudovirus in human lung cells in tissue culture plates and saw that they completely prevented viral entry into the cells.

 When the nanoparticle binds to the virus (about 10 minutes after injection), it chemically signalled macrophages to engulf and destroy the nanoparticle and the attached virus. Macrophages normally engulf nanoparticles, so this merely sped up the process.

Testing the Nanotraps on a pair of donated lungs kept alive with a ventilator, they found that they completely prevented infection.

They also collaborated with researchers at Argonne National Laboratory to test the Nanotraps with a live virus (rather than a pseudovirus) in an in vitro system. They found a 10 times better performance than with neutralising antibodies or ACE2 inhibitor.

The researchers plan further tests, including live virus and its variants.

“That’s what is so powerful about this Nanotrap,” Rosenberg said. “It’s easily modulated. We can switch out different antibodies or proteins or target different immune cells, based on what we need with new variants.”

Storage is simple, as the Nanotraps can be kept in a standard freezer, and administration is simple, using a nasal spray. The researchers said it is also possible to serve as a vaccine by optimisation of the Nanotrap formulation.

Source: Phys.Org

Journal information: Min Chen et al, Nanotraps for the containment and clearance of SARS-CoV-2, Matter (2021). DOI: 10.1016/j.matt.2021.04.005

Categories : Medical Research & TechnologyTags :

Spacesuit Tech Leads to Improved Patient Outcomes

On By ModernMedia

A tech startup is pioneering wearable health technology derived from spacesuit technology.

Maarten Sierhuis, a NASA alum, commented to Rachna Dhamija, a tech veteran and his future cofounder saying, “If your dad would just wear a space suit, I could monitor him”. Both had ageing parents with health issues.

Having worked for 12 years as a senior research scientist at NASA, Sierhuis used sensors and artificial intelligence (AI) to monitor astronauts in space. When astronauts go on spacewalks, their spacesuits contain various sensors that monitor their vitals, with the data being sent to NASA and distributed to the flight surgeon, biomedical engineers, and others. The ground-based crew uses that information to guide its support efforts—perhaps a reminder to drink some water and avert dehydration, or to take a short break to lower heart rate. This technology—called the Brahms Intelligent Agent platform—was licensed to Ejenta from NASA. Now, hospitals and health systems are using it to help better their patient care.

“When we started the company, we just had a very strong conviction that our parents deserve the same level of care NASA provides its astronauts,” Dhamija said.

Ejenta integrates wearable and home sensors that gather data from patients with AI-driven virtual assistants. Using a chat function, patients can use the platform to exchange messages with these assistants, called “intelligent agents” by Ejenta, right from their homes. Clinicians can securely access patient information from the Ejenta platform to better inform their care decisions.

Advances in cloud computing enabled the technology to be adapted from space to the Earth. Ejenta’s founders use a cloud infrastructure to securely collect, store and analyse health data.

Ejenta—whose name is a Bengali slang term for “agents”— is one of them. The company, which was founded in 2012, originally focused on government-related work, including projects for NASA. However, in the last four years, Ejenta evolved into a digital health company. Dhamija said the company’s AI-driven technology is what makes Ejenta unique from other digital health startups.

“There are a lot of healthcare devices available to consumers, but what’s missing is AI and the automation that can turn this data into insights a doctor can use—actionable data to make care more preventative and more proactive,” she said.

Ejenta uses its NASA technology to take data from wearable Internet of Things (IoT) devices and at-home sensors to monitor a patient’s health. Patients can interact with their assistant via text or voice and ask questions like, “What medication do I need to take with breakfast?”and receive an appropriate answer.

A clinical trial with Ejenta by one of the country’s largest healthcare providers, saw heart failure readmissions dropped by 56%. Readmissions come are costly for both patients and the healthcare system, so this application can save considerable amounts of money as well as improving the patient’s quality of life. Ejenta, in separate clinical trials, also contributed to improved outcomes for women who had high-risk pregnancies, reducing risk for gestational diabetes, preterm birth and cesarean sections. These successes were made possible by years of difficult development.

“We had a big challenge adapting our solution, which was originally designed to monitor 12 astronauts in space, to scale up to support thousands of patients across a number of different customer types and a number of different health conditions while still being HIPAA compliant,” Dhamija said.

However, by leveraging Amazon Webs Servers (AWS) as its cloud provider, Ejenta was able to scale up. Dhamija said her team chose AWS because it offers both flexibility and scalability in a secure cloud environment, which is critical when dealing with healthcare data. Ejenta wanted a “cloud provider that had a reputation for providing HIPAA-compliant services our customers would trust,” she said.

Ejenta was part of the Alexa Accelerator, an Amazon programme to help companies incorporate voice technology into their innovations. Before entering the programme, Ejenta had used Alexa to support improved diabetes care management for patients. It continued this work during the accelerator.

“Alexa is one of the only voice-based solutions that gave us the ability to engage customers, whether it’s patients or their family, with voice and do it in a HIPAA-compliant way,” Dhamija said.

Ejenta’s participation in the accelerator led to its involvement in AWS Connections, a program that introduces startups to large organisations that have specific technological or business needs. Through this programme, Ejenta is developing a health and communication management system for astronauts in deep space to relay health informationa and communicate with their families.

“It’s translational, meaning it can be applied for both Earth and space,” Dhamija said. “If you look at some of the problems we face on Earth or space, they do inform each other, so the goal is to have our Earth-based work inform space, and vice versa.”

Source: Forbes

Categories : Medical Research & TechnologyTags :

Harnessing Tailocins, Antibacterial ‘Homing Missiles’

On By ModernMedia

A Berkeley Lab-led team is investigating how to harness tailocins, antibacterial nanomachine ‘weapons’ akin to phages but produced by certain bacteria in suicide attacks against other strains.

“Tailocins are extremely strong protein nanomachines made by bacteria,” explained Vivek Mutalik, a research scientist at Lawrence Berkeley National Laboratory (Berkeley Lab) who studies tailocins and phages, the bacteria-infecting viruses that tailocins appear to be remnants of. “They look like phages but they don’t have the capsid, which is the ‘head’ of the phage that contains the viral DNA and replication machinery. So, they’re like a spring-powered needle that goes and sits on the target cell, then appears to poke all the way through the cell membrane making a hole to the cytoplasm, so the cell loses its ions and contents and collapses.”

Many bacteria can produce tailocins, seemingly under stress conditions. However, the tailocins are only lethal to specific strains, and seem to be used by bacteria to compete with rivals. Since they are so similar to phages, scientists believe that tailocins are repurposed from DNA that was injected into bacterial genomes from viral infections.

According to Mutalik, tailocins kill the bacteria that produce them as they erupt through the membrane, much the way replicated viruses do. However, once released, the tailocins selectively target certain strains and not the host lineage cells.

“They benefit kin but the individual is sacrificed, which is a type of altruistic behavior. But we don’t yet understand how this phenomenon happens in nature,” Mutalik commented. Scientists also don’t know precisely how the stabbing needle plunger of the tailocin functions.

These topics, and tailocins as a whole, are an area of hot research due to the many possible applications. Mutalik and his colleagues in Berkeley Lab’s Biosciences Area along with collaborators at UC Berkeley are interested in harnessing tailocins to better study microbiomes. Other groups are keen to use tailocins as an alternative to traditional antibiotics -which indiscriminately wipe out beneficial strains alongside the bad and are increasingly ineffective due to the evolution of drug-resistance traits.
There is also great interest in using tailocins as an alternative to antibiotics, due to increasing antibiotic resistance and the fact that conventional antibiotics wipe out beneficial strains along with the disease-causing ones.

In their most recent paper, the collaborative Berkeley team explored the genetic basis and physical mechanisms governing how tailocins attack specific strains, and looked at genetic similarities and differences between tailocin producers and their target strains.

Upon examination of 12 strains of tailocin-using soil bacteria, the researchers found that differences in the lipopolysaccharides on the outer membranes determined whether they were targeted by a particular tailocin.

“The bacteria we studied live in a challenging, resource-poor environment, so we’re interested to see how they might be using tailocins to fight for survival,” said co-lead author Adam Arkin, a senior faculty scientist in the Biosciences Area and technical co-manager of the Ecosystems and Networks Integrated with Genes and Molecular Assemblies (ENIGMA) Scientific Focus Area. Arkin observed that although bacteria can easily be induced to produce tailocins in the lab, as well as scale up for mass production for medicinal applications, it is not well understood how bacteria deploy tailocins in their natural environment, and how or why particular strains are so precisely targeted.

“Once we understand the targeting mechanisms, we can start using these tailocins ourselves,” Arkin added. “The potential for medicine is obviously huge, but it would also be incredible for the kind of science we do, which is studying how environmental microbes interact and the roles of these interactions in important ecological processes, like carbon sequestration and nitrogen processing.”

At the moment, it is difficult to observe what is happening in a bacterial community, but tailocins could remove individual strains with precision to allow a better understanding of the situation.

Follow-up studies being conducted involve taking atomic-level images of the taolicins in action.

Source: SciTech Daily

Journal information: “Systematic discovery of pseudomonad genetic factors involved in sensitivity to tailocins” by Sean Carim, et al., 1 March 2021, The ISME Journal. DOI: 10.1038/s41396-021-00921-1